10 registrations that name copper as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 10 registrations
Status
Phase
7US sites across 5 states
1
2 to 4
5 to 19
20 or more
All 10 registrations
RecruitingNCT07471542
Copper Supplementation in Cirrhosis
No phase
University of Washington
About 30 people
Starts Mar 15, 2026 (estimated)
In plain words A study of copper in people 18 and older, run by University of Washington. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Cirrhosis; Chronic Liver Disease; Fibrosis; Infection.
Adult patients age 18 or older with confirmed diagnosis of cirrhosis based on clinical history, exam, imaging, laboratory or histological criteria;
Cirrhosis patients whose serum or plasma Cu are below the normal range (80-155 ug/dL for women and 70-140 ug/dL for men);
Cirrhosis patients whose serum or plasma Cu are in the normal range but exhibit at least one clinical feature that has been associated with Cu deficiency.
The exclusion criteria are on the listing.
What it tests, as registered
Copper Gluconate
Registered summary
End stage liver disease or cirrhosis is a major cause of mortality in the United States and the world. Other than targeting the underlying cause, such as alcohol cessation and antiviral therapy, very few medical treatments can change the natural history of cirrhosis. Malnutrition is one of the few potentially modifiable factors that have been associated with cirrhosis severity and poor prognosis. The transition metal copper (Cu) is an essential trace metal that must be acquired from diet. Its metabolism is primarily regulated by the liver in its role as a master regulator of nutrients. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05210374
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Phase 1
Case Comprehensive Cancer Center
About 24 people
Started Mar 9, 2023
In plain words A Phase 1 study of copper in people 18 and older, run by Case Comprehensive Cancer Center. It plans to enroll about 24 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Relapsed Sarcomas.
Must have histologically confirmed relapsed or refractory sarcoma.
Must have measurable disease by RECIST criteria at study enrollment
Performance status of Karnofsky/Lansky ≥50%
Must have normal organ and marrow function as defined below:
12 more inclusion criteria and the exclusion criteria are on the listing.
The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.
Where, as registered
1 US site in 1 state.
RecruitingNCT05376878
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
Phase 4
City of Hope Medical Center
About 10 people
Started Dec 21, 2022
In plain words A Phase 4 study of copper in people 18 and older, run by City of Hope Medical Center. It plans to enroll about 10 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain.
Documented informed consent of the participant and/or legally authorized representative
Women with documented metastatic HER2 positive breast cancer (American Society of Clinical Oncology \[ASCO\] College of American Pathologist \[CAP\] guidelines) who have brain metastases
Age > 18 years
Eastern Cooperative Oncology Group (ECOG) 0-2
11 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Copper Cu 64-DOTA-Trastuzumab; Magnetic Resonance Imaging; Positron Emission Tomography; Trastuzumab; Trastuzumab Deruxtecan
Registered summary
This clinical trial examines an investigational scan (64Cu-DOTA-trastuzumab positron emission tomography \[PET\]/magnetic resonance imaging \[MRI\]) in imaging patients with HER2+ breast cancer that has spread to the brain (brain metastasis). Diagnostic procedures, such as 64Cu-DOTA-trastuzumab PET/MRI, may help find HER2+ breast cancer that has spread to the brain and determine whether cancer in the brain takes up trastuzumab, which may predict for response to trastuzumab deruxtecan (the standard of care chemotherapy).
Where, as registered
1 US site in 1 state.
RecruitingNCT06736054
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
Phase 1
Hoag Memorial Hospital Presbyterian
About 8 people
Started Oct 14, 2024
In plain words A Phase 1 study of copper in male participants 18 and older, run by Hoag Memorial Hospital Presbyterian. It plans to enroll about 8 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Prostate Adenocarcinoma.
Biopsy proven prostate adenocarcinoma
Age ≥ 18 years
ECOG 0 or 1
At least one site of PSMA-positive disease on a PSMA-targeted PET/CT performed within 30 days of trial recruitment
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Copper 61-PSMA PET/CT
Registered summary
Molecular Imaging (MI) uses tracers which emit radiation to provide clinically valuable imaging for patient with cancer. Most current MI agents utilize Fluorine 18 or Gallium 68 as the positron emitter for PET imaging. However, these isotopes have short half-lives which limit the geographic distribution range of tracers made with these isotopes. Copper 61 (61Cu) has a 3.3 hour half-life, which would allow for far greater distribution range following radiotracer production. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06016855
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Phase 4
Vanderbilt-Ingram Cancer Center
About 6 people
Started May 31, 2024
In plain words A Phase 4 study of copper in people 18 and older, run by Vanderbilt-Ingram Cancer Center. It plans to enroll about 6 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Digestive System Neuroendocrine Tumor G1; Digestive System Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Malignant Neoplasm in the Liver; Pancreatic Neuroendocrine Tumor G1; Pancreatic Neuroendocrine Tumor G2.
Signed and dated written informed consent
Male or female >= 18 years of age on the day of signing informed consent
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Histologically confirmed well-differentiated gastrointestinal or pancreatic neuroendocrine tumor that is grade 1 or grade 2 (Ki-67 =< 20%)
11 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Tumor Debulking; Lutetium Lu 177 Dotatate; Computed Tomography; Magnetic Resonance Imaging; Copper Cu 64 Dotatate; Positron Emission Tomography
Registered summary
This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1 or 2, somatostatin receptor (SSTR) positive, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have spread from where they first started (primary site) to the liver (hepatic metastasis). Lutetium Lu 177 dotatate is a radioactive drug that uses targeted radiation to kill tumor cells. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT04965545
Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease
Observational
Second Affiliated Hospital, Zhejiang University, School of Medicine
About 1,000 people
Started Jan 1, 2004
In plain words An observational study of copper in people 6 to 65, run by Second Affiliated Hospital, Zhejiang University, School of Medicine. It plans to enroll about 1,000 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 to 65. Conditions: Wilson Disease.
genetically diagnosed patients with wilson disease
The exclusion criteria are on the listing.
What it tests, as registered
low copper diet
Registered summary
The investigators aimed to identify factors associated with symptoms and features of Wilson disease from a large cohort during long-term follow-up
Where, as registered
No US site; China (1).
Not yet recruitingNCT07843537
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Phase 2
M.D. Anderson Cancer Center
About 30 people
Starts Mar 1, 2027 (estimated)
In plain words A Phase 2 study of copper in people 18 and older, run by M.D. Anderson Cancer Center. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Thoracic Cancer.
Histologically confirmed locally advanced or metastatic disease of any histology that will receive chest radiation
Scheduled to receive RT as part of definitive local consolidation therapy (LCT) (not palliative)
Induction systemic therapy allowed, but just not concurrently given (washout for at least 3 weeks before start of CDT and RT)
Age ≥18 years.
10 more inclusion criteria and the exclusion criteria are on the listing.
This study is being done to test whether adding two drugs-disulfiram and copper gluconate-to radiation therapy can help overcome this resistance and improve treatment outcomes. When disulfiram is combined with copper, it forms a substance that may increase stress within cancer cells and lead to a specific type of cancer cell death knowns as "cuproptosis".
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07608627
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
Phase 1
City of Hope Medical Center
About 15 people
Starts Dec 16, 2026 (estimated)
In plain words A Phase 1 study of copper in people 18 and older, run by City of Hope Medical Center. It plans to enroll about 15 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8.
Documented informed consent of the participant and/or legally authorized representative
Age: ≥ 18 years
Karnofsky > 70%
Advanced (locally or metastatic), histologically confirmed pancreatic adenocarcinoma
11 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Biospecimen Collection; Copper Cu 64-DOTA-A2DM; Positron Emission Tomography; Radioconjugate
Registered summary
This clinical trial tests the safety, side effects, best dose and feasibility of using 64Cu-DOTA A2 scFv-Fc2 DM with positron emission tomography for the imaging of patients with PSCA-expressing pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 64Cu-DOTA A2 scFv-Fc2 DM. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07164534
A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.
Phase 3
Tata Memorial Hospital
About 316 people
Starts Mar 2026 (estimated)
In plain words A Phase 3 study of copper in female participants 18 and older, run by Tata Memorial Hospital. It plans to enroll about 316 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Uterine Cervical Neoplasm.
Female subjects aged 18 years or above with histologically proven locally advanced squamous cell or adenocarcinoma of the cervix
Subjects eligible for RT and planned for definitive RT +/- chemotherapy with brachytherapy.
Subjects who exceed the dose constraints of:
Rectum/sigmoid D 2cm³ EQD2 ³ by more than 70 Gy, or
10 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Sodium-copper-chlorophyllin, a semi-synthetic derivative of chlorophyll, is made up of a mixture of sodium copper salts.
Registered summary
Cervical cancer is the second most common cancer in Indian women, and most patients are diagnosed at advanced stages. The standard treatment for these stages is concurrent chemoradiotherapy, but this can cause long-term side effects such as bladder inflammation, strictures, ulcers, and tissue damage, which negatively impact patients' quality of life. Previous studies have shown that oral sodium-copper-chlorophyllin can help reduce radiation-related side effects in rectal, prostate, and cervical cancer patients. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT01777919
Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform
Phase 2
Olympion Medical Center
About 32 people
Starts Jan 2027 (estimated)
In plain words A Phase 2 study of copper in people 18 and older, run by Olympion Medical Center. It plans to enroll about 32 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Glioblastoma Multiforme.
Histopathologically confirmed diagnosis of glioblastoma (World Health Organization \[WHO\] grade IV astrocytoma). Patients must be newly diagnosed with unifocal supratentorial GBM amenable to gross total resection (< 1 cm.
Patient must have undergone a gross total surgical resection of the tumor mass with post-surgical MRI (performed within 72 hours after operation) demonstration of adequacy defined as < 1.0 cm of residual enhancement away from resection…
Ability to start disulfiram on the 5th postoperative day
≥ 18 years of age
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Temozolomide; Disulfiram; Copper
Registered summary
Glioblastoma multiform (GBM) is the most common malignant primary brain tumor in adults. Despite maximal treatment tumor relapse occurs regularly accompanied by unfavourable prognosis. Among other reasons, it is believed that this could be in part due to the existence of the so-called tumor stem cells (TSCs), a cellular subfraction within GBM which escape therapy by being highly resistant to irradiation and chemotherapy and thus constituting the source of tumor recurrence. GBM, like many other cancers, show a sub-population of aldehyde dehydrogenase (ALDH) overexpressing TSCs. The full summary is on the listing.